{"id":"clopidogrel-and-metoprolol","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Bleeding"},{"rate":"2-4","effect":"Bradycardia"},{"rate":"2-3","effect":"Fatigue"},{"rate":"1-2","effect":"Dyspnea"},{"rate":"1-2","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clopidogrel is a P2Y12 platelet receptor antagonist that prevents platelet activation and clot formation, while metoprolol is a beta-1 selective adrenergic antagonist that decreases heart rate, contractility, and blood pressure. Together, they provide dual antiplatelet and hemodynamic benefits for cardiovascular protection.","oneSentence":"This combination drug uses clopidogrel to inhibit platelet aggregation and metoprolol to reduce heart rate and blood pressure, together reducing cardiovascular events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:55.856Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary prevention after acute coronary syndrome or myocardial infarction"},{"name":"Reduction of cardiovascular events in patients with coronary artery disease"}]},"trialDetails":[{"nctId":"NCT06877390","phase":"NA","title":"Effect of Enhanced External Counterpulsation","status":"COMPLETED","sponsor":"Chongming Hospital Affiliated to Shanghai University of Health & Medicine Sciences","startDate":"2023-11-01","conditions":"Enhanced External Counterpulsation (EECP), Acute Myocardial Infarction (AMI), Drug-coated Balloon","enrollment":60},{"nctId":"NCT04744571","phase":"NA","title":"Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2021-02","conditions":"Coronary Artery Disease, Coronary Occlusion, Percutaneous Coronary Intervention","enrollment":200},{"nctId":"NCT04661709","phase":"PHASE4","title":"Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-03-01","conditions":"Coronary Heart Disease, Unstable Angina, Chinese Herbal Medicine","enrollment":502},{"nctId":"NCT03372785","phase":"","title":"The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2018-04-10","conditions":"Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention, Coronary Artery Disease","enrollment":240},{"nctId":"NCT02767401","phase":"PHASE4","title":"The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2015-09-15","conditions":"Hibernation, Myocardial, Complete Occlusion of Coronary Artery","enrollment":200},{"nctId":"NCT02191358","phase":"","title":"YouScript IMPACT Registry","status":"COMPLETED","sponsor":"Genelex Corporation","startDate":"2014-10","conditions":"Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation","enrollment":800},{"nctId":"NCT00222573","phase":"PHASE4","title":"Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction","status":"COMPLETED","sponsor":"University of Oxford","startDate":"1999-07","conditions":"Acute Myocardial Infarction","enrollment":46000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"clopidogrel and metoprolol","genericName":"clopidogrel and metoprolol","companyName":"University of Oxford","companyId":"university-of-oxford","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug uses clopidogrel to inhibit platelet aggregation and metoprolol to reduce heart rate and blood pressure, together reducing cardiovascular events. Used for Secondary prevention after acute coronary syndrome or myocardial infarction, Reduction of cardiovascular events in patients with coronary artery disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}